Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fulcrum Therapeutics
Biotech
Sanofi's $80M bet on Fulcrum dystrophy drug ends in phase 3 fail
Just four months after Sanofi bet $80 million upfront on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure.
James Waldron
Sep 12, 2024 9:30am
Sanofi pays Fulcrum $80M for rights to phase 3 rare disease drug
May 13, 2024 7:09am
Bayer undergoes leadership shake-up—Chutes & Ladders
Mar 22, 2024 9:30am
Fulcrum's SCD program is back in business after FDA lifts hold
Aug 22, 2023 8:33am
Cancer concerns behind FDA hold on Fulcrum's sickle cell med
Mar 9, 2023 10:59am
Fulcrum's clinical hold caps off tough week for sickle cell
Feb 24, 2023 9:55am
